Acquisition - March 15, 2017
The new Teva grows stronger – in Norway
In August last year Teva completed its acquisition of Actavis Generics and the new Teva in Norway will be among the 15 largest companies in the country. The new company will be named Teva and will be located at Teva’s facilities in Hagaløkkveien in Asker. Employees from Actavis moved in with the Teva team in […]
Acquisition - March 12, 2015
AstraZeneca Buys More Respiratory Business
AstraZeneca recently acquired the rights to Actavis’ branded respiratory business in the US and Canada, according to a company announcement. As part of the agreement, AstraZeneca is paying Actavis $600 million of initial consideration and agreed to pay low single-digit royalties above a certain revenue threshold. AstraZeneca also paid Actavis an additional $100 million for […]
Acquisition - February 18, 2015
AstraZeneca to Acquire Actavis’ Branded Respiratory Side in U.S., Canada
AstraZeneca plans to acquire the rights to Actavis’ branded respiratory business in the U.S. and Canada for an initial consideration of $600 million on completion and low single-digit royalties above a certain revenue threshold. When the transaction is finalized, AstraZeneca will own the development and commercial rights in the US and Canada to TudorzaTM PressairTM […]
Intellectual Property - June 27, 2014
Orexo commences patent infringement litigation against Actavis
Orexo has filed a patent infringement action in the US District Court for the District of Delaware, against Actavis Elizabeth LLC and its parent company Actavis. The lawsuit was filed in response to an Abbreviated New Drug Application (“ANDA”) filed by Actavis. In its application, Actavis seeks to market and sell generic versions of Orexo’s patented […]
Acquisition - February 18, 2014
Actavis to Buy Forest Labs
Actavis PLC plans to buy Forest Laboratories Inc. for about $25 billion. “With this strategic combination, we create an innovative new model in specialty pharmaceuticals leadership, with size and scale, a balanced offering of strong brands and generics, a focus on strategic, lower-risk drug development, and – most important – the ability to drive sustainable […]
Acquisition - June 7, 2013
Enzymatica signs agreement with Actavis
Enzymatica and the international pharmaceuticals company, Actavis, have signed a letter of intent on the sale of Enzymatica’s cold treatment product, ColdZyme Mouth Spray, on the Nordic market. Under the agreement, the product will be on sale in around 3,200 pharmacies and a large number of stores, including health food retailers, in the Nordic region. Actavis […]